Dr. Martin Tolar, CEO of Alzheon joins BNN Bloomberg to discuss the Food and Drug Administration's approval of Biogen's drug to treat Alzheimer's patients. He says this is great news for everyone working in the space since it's the first drug in almost 20 years that has been approved.